60 related articles for article (PubMed ID: 31017498)
1. Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.
Abel GA; Hebert D; Lee C; Rollison D; Gillis N; Komrokji R; Foran JM; Liu JJ; Al Baghdadi T; Deeg J; Gore S; Saber W; Wilson S; Otterstatter M; Thompson J; Borchert C; Padron E; DeZern A; Cella D; Sekeres MA
Blood Adv; 2023 Jul; 7(14):3506-3515. PubMed ID: 37146263
[TBL] [Abstract][Full Text] [Related]
2. A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm.
Dong A; Pan X; Lin CW; Huang YW; Krause H; Pan P; Baim A; Thomas MJ; Chen X; Yu J; Michaelis L; Liu P; Wang LS; Atallah E
J Cancer Prev; 2022 Jun; 27(2):129-138. PubMed ID: 35864858
[TBL] [Abstract][Full Text] [Related]
3. [Study of a patient with Myelodysplastic/myeloproliferative neoplasm with co-morbid neutrophilia and a novel NCOR1::GLYR1 fusion gene].
Lei Y; Zhao X; Zhao H; Cheng Y; Wang S; Li J; Zhu Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2024 Apr; 41(4):404-410. PubMed ID: 38565504
[TBL] [Abstract][Full Text] [Related]
4. Assessment of a novel NRAS in-frame tandem duplication causing a myelodysplastic/myeloproliferative neoplasm.
Beckmann CCA; Ramamoorthy S; Trompouki E; Driever W; Schwarz-Furlan S; Strahm B; Yoshimi A; Niemeyer CM; Erlacher M; Kapp FG
Exp Hematol; 2024 May; 133():104207. PubMed ID: 38522505
[TBL] [Abstract][Full Text] [Related]
5. Coexisting primary tumors from esophageal cancer and myelodysplastic syndromes: A case report.
Imamura H; Tamura S; Hattori H; Kidogami S; Mokutani Y; Kishimoto T; Hashimoto Y; Hirose H; Yoshioka S; Kuwayama M; Endo S; Sasaki Y
Clin Case Rep; 2021 Sep; 9(9):e04872. PubMed ID: 34584722
[TBL] [Abstract][Full Text] [Related]
6. Abnormal B-lymphoblasts in myelodysplastic syndromes and myeloproliferative neoplasms other than chronic myeloid leukemia.
Chan A; Kumar P; Gao Q; Baik J; Sigler A; Londono D; Liu Y; Arcila ME; Dogan A; Zhang Y; Roshal M; Xiao W
Cytometry B Clin Cytom; 2023 May; 104(3):243-252. PubMed ID: 34897961
[TBL] [Abstract][Full Text] [Related]
7. Genomic trajectory in leukemogenesis of myeloproliferative neoplasms: a case report.
Chen Y; Talukder R; Merritt BY; King KY; Kimmel M; Rivero G; Sosa R
BMC Med Genomics; 2021 May; 14(1):137. PubMed ID: 34022887
[TBL] [Abstract][Full Text] [Related]
8. The cellular origins of cancer with particular reference to the gastrointestinal tract.
Alison MR
Int J Exp Pathol; 2020 Oct; 101(5):132-151. PubMed ID: 32794627
[TBL] [Abstract][Full Text] [Related]
9. Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review.
Roupie AL; de Boysson H; Thietart S; Carrat F; Seguier J; Terriou L; Versini M; Queyrel V; Groh M; Benhamou Y; Maurier F; Decaux O; d'Aveni M; Rossignol J; Galland J; Solary E; Willems L; Schleinitz N; Ades L; Dellal A; Samson M; Aouba A; Fenaux P; Fain O; Mekinian A;
Autoimmun Rev; 2020 Feb; 19(2):102446. PubMed ID: 31838164
[TBL] [Abstract][Full Text] [Related]
10. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
11. Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
Xie W; Chen Z; Wang SA; Hu S; Li S; Miranda RN; Medeiros LJ; Tang G
Leuk Lymphoma; 2019 Dec; 60(12):2993-3001. PubMed ID: 31017498
[TBL] [Abstract][Full Text] [Related]
12. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
13. Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.
Hebeda K; Boudova L; Beham-Schmid C; Orazi A; Kvasnicka HM; Gianelli U; Tzankov A
Ann Hematol; 2021 Jan; 100(1):117-133. PubMed ID: 33128619
[TBL] [Abstract][Full Text] [Related]
14. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
15. Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN.
Mestrum SGC; de Wit NCJ; Drent RJM; Hopman AHN; Ramaekers FCS; Leers MPG
Cytometry B Clin Cytom; 2021 May; 100(3):322-330. PubMed ID: 32857909
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]